Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 Omicron BA.2 infection, hospitalisation, severe complications, cardiovascular disease and mortality in patients with diabetes mellitus: A case control study

[1]  Xia Li,et al.  Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series , 2022, The Lancet Healthy Longevity.

[2]  Xinjie Li,et al.  Antibody efficacy of inactivated vaccine boosters (CoronaVac) against Omicron variant from a 15-month follow-up study , 2022, Journal of Infection.

[3]  E. Lau,et al.  Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong, January–March 2022 , 2022, medRxiv.

[4]  S. Katikireddi,et al.  Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil , 2022, Nature Medicine.

[5]  J. Peiris,et al.  Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study , 2022, The Lancet Regional Health - Western Pacific.

[6]  L. Poon,et al.  Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination , 2022, Nature Medicine.

[7]  G. Screaton,et al.  Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study , 2022, The Lancet.

[8]  B. Cowling,et al.  Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study , 2021, The Lancet Infectious Diseases.

[9]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[10]  P. Preux,et al.  The Lancet Regional Health-Western Pacific , 2020 .